Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

Blockade of Interferon-γ Normalizes Interferon-Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus

(2015) Andrew A. Welcher et al.   Arthritis & Rheumatology

Systemic lupus erythematosus

(2014) Larissa Lisnevskaia et al.   LANCET

Modular Transcriptional Repertoire Analyses of Adults With Systemic Lupus Erythematosus Reveal Distinct Type I and Type II Interferon Signatures

(2014) Laurent Chiche et al.   Arthritis & Rheumatology

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

(2013) Daniel J Wallace et al.   ANNALS OF THE RHEUMATIC DISEASES

Sifalimumab, a Human Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study

(2013) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

Anti-interferon alpha treatment in SLE

(2013) Kyriakos A. Kirou et al.   CLINICAL IMMUNOLOGY

Interferon-  Abrogates the Suppressive Effect of Apoptotic Cells on Dendritic Cells in an In Vitro Model of Systemic Lupus Erythematosus Pathogenesis

(2013) L. Abeler-Dorner et al.   JOURNAL OF RHEUMATOLOGY

Type I interferon blockade in systemic lupus erythematosus: where do we stand?

(2013) B. R. Lauwerys et al.   RHEUMATOLOGY

Biomarkers for systemic lupus erythematosus

(2012) Ronald Herbst et al.   International Journal of Rheumatic Diseases

Glucocorticoid use and abuse in SLE

(2012) G. Ruiz-Irastorza et al.   RHEUMATOLOGY

Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus

(2012) Yihong Yao et al.   ARTHRITIS RESEARCH & THERAPY

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon   monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

(2011) J. T. Merrill et al.   ANNALS OF THE RHEUMATIC DISEASES

Development of the CLASI as a Tool to Measure Disease Severity and Responsiveness to Therapy in Cutaneous Lupus Erythematosus

(2011) Rachel Klein et al.   ARCHIVES OF DERMATOLOGY

Quality of life in cutaneous lupus erythematosus

(2011) Rachel Klein et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The interferon-α signature of systemic lupus erythematosus

(2010) G. Obermoser et al.   LUPUS

Numerical scoring for the BILAG-2004 index

(2010) Chee-Seng Yee et al.   RHEUMATOLOGY

Building a Measure of Fatigue: The Functional Assessment of Chronic Illness Therapy Fatigue Scale

(2010) Eleanor Smith et al.   PM&R

Novel evidence-based systemic lupus erythematosus responder index

(2009) Richard A. Furie et al.   ARTHRITIS AND RHEUMATISM

Lupus: improving long-term prognosis

(2008) A Doria et al.   LUPUS